DSpace Repository

Tocilizumab in COVID-19: Enthusiasm vs. evidence

Show simple item record

dc.contributor.author Zena-Huancas, P.
dc.contributor.author Leon-Jimenez, F.
dc.contributor.author Bryce-Alberti, M.
dc.contributor.author Portmann Baracco, Arianna Sibila
dc.date.accessioned 2021-12-12T20:24:53Z
dc.date.available 2021-12-12T20:24:53Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/10191
dc.description.abstract Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials en_US
dc.language.iso eng
dc.publisher Wolters Kluwer Health
dc.relation.ispartofseries Lung India
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject adult en_US
dc.subject Article en_US
dc.subject C reactive protein en_US
dc.subject clinical article en_US
dc.subject clinical decision making en_US
dc.subject clinical feature en_US
dc.subject clinical trial en_US
dc.subject coronavirus disease 2019 en_US
dc.subject COVID-19 en_US
dc.subject disease severity en_US
dc.subject drug efficacy en_US
dc.subject drug safety en_US
dc.subject evidence based practice en_US
dc.subject female en_US
dc.subject high flow nasal cannula therapy en_US
dc.subject human en_US
dc.subject life threat en_US
dc.subject lung embolism en_US
dc.subject male en_US
dc.subject middle aged en_US
dc.subject mortality rate en_US
dc.subject outcome assessment en_US
dc.subject pneumopericardium en_US
dc.subject randomized controlled trial (topic) en_US
dc.subject single drug dose en_US
dc.subject tocilizumab en_US
dc.subject treatment en_US
dc.title Tocilizumab in COVID-19: Enthusiasm vs. evidence en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.4103/lungindia.lungindia_766_20
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.07
dc.relation.issn 0974-598X


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics